Can I Take Melatonin With Synthroid (Levothyroxine)?

Levothyroxine (brand name Synthroid, among others) is a synthetic form of the thyroid hormone thyroxine (T4), FDA-approved for hypothyroidism and TSH suppression in certain thyroid cancer patients. Melatonin is a hormone sold in the United States as an unregulated dietary supplement, not an FDA-approved drug, in doses typically ranging from 0.5 mg to 10 mg. This article addresses whether the two can be taken together, not whether either is right for a given diagnosis.

No published evidence shows that melatonin changes how levothyroxine is absorbed or broken down in the body. The two do not compete for the same gut transporters or liver enzymes as far as current research indicates. The open question is different: melatonin and thyroid-stimulating hormone (TSH) share a circadian relationship, and some human and animal research has explored whether exogenous melatonin can blunt the nocturnal TSH rise or affect glucose handling. For most people taking standard replacement doses of levothyroxine and low-dose melatonin (0.5 mg to 1 mg) at bedtime, the practical risk is considered low, but it is not zero, and it has not been rigorously studied in a large population of levothyroxine-treated patients specifically. Separating the two doses by taking levothyroxine in the morning on an empty stomach and melatonin at night, and rechecking TSH at your next routine follow-up after starting melatonin, is a reasonable and low-cost way to manage the uncertainty.

What is actually established

• Levothyroxine and melatonin do not share a known pharmacokinetic drug interaction. There is no documented competition for absorption, metabolism, or clearance.
• Levothyroxine absorption is well established to be sensitive to food, coffee, calcium, iron, and antacids taken close to the dose. Standard labeling instructs patients to take levothyroxine on an empty stomach, generally 30 to 60 minutes before food, or as directed by the prescriber for bedtime dosing regimens.
• TSH secretion follows a circadian pattern with a nocturnal peak, and melatonin secretion also follows a circadian pattern. That these two systems are physiologically linked in some way is well described in endocrine physiology, separate from any question about melatonin supplements.
• Chronically over-suppressed TSH (well below the reference range for a prolonged period), as intentionally targeted in some thyroid cancer patients, is an established risk factor tracked by endocrinologists for downstream effects including bone density loss and atrial arrhythmia risk. This is a guideline-level concern about suppressive therapy generally, independent of melatonin.

What is pharmacologically plausible but not established in levothyroxine patients

• Older in-vitro research has examined melatonin's direct effects on human thyroid tissue outside the body, raising the general question of whether melatonin could have some local effect on thyroid hormone synthesis or signaling (Kandror et al., 1997). This is bench research on excised tissue, not a clinical trial in people taking oral melatonin supplements, and it should not be read as proof that oral melatonin meaningfully changes thyroid function in a person already on replacement therapy.
• It is biologically plausible that supplemental melatonin, particularly at higher doses, could modestly influence the nocturnal TSH signal given the overlapping circadian machinery. Whether this produces a measurable, clinically important shift in patients already stabilized on levothyroxine has not been demonstrated in a well-controlled trial that this article can verify.
• Melatonin's reported effects on insulin secretion and glucose tolerance at higher doses (generally above 3 to 5 mg) come from research in the general population, not from levothyroxine-treated hypothyroid patients specifically. Whether hypothyroid patients on stable replacement carry extra risk from this effect is not established; it is a reasonable point of caution rather than a proven added harm.

What is not established

• No trial has demonstrated that melatonin, at typical over-the-counter doses, causes a clinically meaningful or lasting change in TSH in patients stabilized on levothyroxine replacement.
• There is no dose-response data from a verified levothyroxine-specific study that this article can cite with confidence. Claims giving a precise TSH change in mIU/L for a specific melatonin milligram dose in hypothyroid patients should be treated as unverified until checked against the primary literature; readers and clinicians should not rely on such numbers for dosing decisions.
• Melatonin's effect, if any, on thyroid autoantibodies (such as TPO antibodies) or on the course of Hashimoto's thyroiditis in humans has not been established by a well-designed clinical trial.
• Melatonin's safety in pregnancy, including in pregnant patients being treated for hypothyroidism, has not been established by adequate human trial data. Professional obstetric guidance does not recommend melatonin as a routine sleep aid in pregnancy for this reason.

Evidence-status interaction assessment: melatonin and levothyroxine

Timing: does it matter when I take each one?

Levothyroxine's absorption requirements are the more rigid constraint here, not melatonin. Standard prescribing guidance calls for levothyroxine to be taken on an empty stomach, generally 30 to 60 minutes before breakfast, with calcium, iron, and antacids kept at least four hours away regardless of melatonin use.

Most people take levothyroxine in the morning and melatonin at bedtime, which creates a natural separation of many hours. That schedule addresses any residual concern about direct interaction and requires no special adjustment.

A smaller number of patients take levothyroxine at bedtime, sometimes because morning dosing is inconvenient or because a prescriber found it easier to control absorption at night. Evening thyroxine dosing has been studied and can achieve similar control to morning dosing in some patients, but this is a prescribing decision that should be made with a physician, not a self-directed switch. Patients on bedtime levothyroxine who also want to take melatonin should separate the two doses by at least an hour as a precaution, and confirm the plan with their pharmacist or prescriber.

Monitoring: what to actually do after starting melatonin

There is no dedicated clinical trial establishing an ideal monitoring interval specifically for melatonin plus levothyroxine. In general endocrine practice, any meaningful change to a patient's supplement regimen while on levothyroxine is a reasonable trigger for an earlier-than-scheduled TSH check, commonly in the range of six to eight weeks, rather than waiting for the next routine annual or semi-annual test. This is standard practice for medication changes generally in thyroid management, not a melatonin-specific guideline recommendation, and the exact interval should be set by the prescriber based on the patient's TSH target and history.

Patients with a suppression target (TSH intentionally kept low after thyroid cancer treatment) and patients whose TSH is already near the edge of their target range are the two groups for whom this follow-up matters most.

Special situations

Pregnancy. Melatonin crosses the placenta, and controlled human safety data in pregnancy are limited. Pregnant patients being treated for hypothyroidism, gestational or pre-existing, should not start melatonin without checking with their obstetric or endocrine provider first.

Older adults. TSH reference ranges shift somewhat with age, and endogenous melatonin production tends to decline. Whether this changes the risk-benefit balance of supplemental melatonin in older levothyroxine patients has not been specifically studied; general caution and the same monitoring approach apply.

Thyroid cancer survivors on suppressive therapy. This is the group where caution matters most. Because the TSH target is already intentionally low, any additional TSH-lowering effect, even a modest one, moves the patient further from a range considered safe long-term for bone and cardiac health. This subgroup should discuss melatonin with their endocrinologist before starting, rather than trying it and monitoring after the fact.

Biotin: a separate, unrelated issue worth flagging

Biotin does not interact pharmacodynamically with levothyroxine or melatonin, but high-dose biotin (commonly found in hair, skin, and nail supplements, often well above 5 mg per day) can interfere with certain thyroid immunoassays and produce a falsely low TSH reading, mimicking over-replacement or hyperthyroidism. If a patient is taking a high-dose biotin supplement, stopping it roughly two to three days before a thyroid blood draw is a standard step to avoid this lab artifact. This is a testing issue, not a true hormonal interaction, and should not be confused with the melatonin question above.

What to tell your prescriber or pharmacist

• Your current TSH value and your target range, if you know it.
• The melatonin dose and brand you plan to use (starting at 0.5 to 1 mg is a reasonable low-risk starting point for most adults, pending your prescriber's input).
• Whether you take levothyroxine in the morning or at bedtime.
• Any other supplements that could affect thyroid function or thyroid lab accuracy, including biotin, iron, calcium, and selenium.

Alternatives if melatonin is not the right fit

If a prescriber advises against melatonin, or TSH shifts after starting it, other options exist. Cognitive behavioral therapy for insomnia (CBT-I) is considered a first-line, non-pharmacologic treatment for chronic insomnia and has no known drug interaction with levothyroxine. Basic sleep hygiene measures (consistent sleep and wake times, reduced evening light exposure, a cool bedroom) are standard first steps recommended by sleep medicine guidelines. Prescription options such as low-dose trazodone or other sedative-hypnotics carry their own separate risk profiles and should be discussed individually with a prescriber; this article does not evaluate their thyroid interaction evidence in detail.

When to seek care rather than self-manage

Contact your prescriber promptly, rather than adjusting doses on your own, if you notice new symptoms of thyroid imbalance after starting melatonin, such as unexplained heart palpitations, significant fatigue, unexplained weight change, or a TSH result that has moved meaningfully outside your target range. This article does not provide individualized dosing advice for either levothyroxine or melatonin; those decisions belong with your treating clinician.